within Pharmacolibrary.Drugs.ATC.L;

model L03AX08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.2 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,
    adminCount     = 1,
    Vd             = 0.006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Poly ICLC (polyinosinic-polycytidylic acid stabilized with poly-L-lysine and carboxymethylcellulose) is a synthetic double-stranded RNA used as an immune modulator and adjuvant, primarily for research and investigational purposes in oncology and infectious diseases to stimulate innate immune responses via toll-like receptor 3 (TLR3). It is not approved for routine clinical use.</p><h4>Pharmacokinetics</h4><p>No pharmacokinetic parameters have been reported in published literature for poly ICLC in humans. The following values are placeholders based on general estimates for large molecular weight biologics administered intramuscularly.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L03AX08;
